The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Mantle Cell Lymphoma Therapeutics Market During 2026–2030?
The mantle cell lymphoma therapeutics market has demonstrated robust growth in recent years. It is anticipated to expand from $2.6 billion in 2025 to $2.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. This historical expansion can be attributed to the increasing incidence of mantle cell lymphoma, progress in chemotherapeutic agents, rising adoption by hospitals and research institutes, the development of monoclonal antibody therapies, and advancements in parenteral administration techniques.
The mantle cell lymphoma therapeutics market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $3.81 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this growth during the forecast timeframe include the wider availability of targeted and combination therapies, an increase in oral BTK and BCL2 inhibitors, the implementation of precision medicine strategies, greater funding for immunotherapy research, and an expanding elderly patient demographic. Key trends expected over the forecast period encompass the growth of targeted therapies, progress in immunotherapy, the uptake of oral therapeutics, the incorporation of personalized medicine, and the ongoing creation of combination therapies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10813&type=smp
What Drivers Are Expected To Influence The Mantle Cell Lymphoma Therapeutics Market During The Forecast Period?
The anticipated increase in the prevalence of mantle cell lymphoma is expected to propel the growth of the mantle cell lymphoma therapeutics market going forward. Mantle cell lymphoma (MCL) is a specific type of non-Hodgkin lymphoma (NHL), which is a form of cancer that affects the lymphatic system. Therapeutics designed for Mantle Cell Lymphoma are instrumental in reducing the disease’s occurrence by effectively treating and managing the condition, leading to improved patient outcomes, prolonged survival, and a reduced disease burden. For instance, in February 2024, according to Lymphoma Action, a UK-based charity dedicated to lymphoma, approximately 600 people in the UK are diagnosed with mantle cell lymphoma each year; this condition is observed more often in men than women and is typically identified in individuals who are middle-aged or older. Therefore, the rise in the prevalence of mantle cell lymphoma is driving the growth of the mantle cell lymphoma therapeutics market.
How Are The Various Segments Of The Mantle Cell Lymphoma Therapeutics Market Categorized?
The mantle cell lymphoma therapeutics market covered in this report is segmented –
1) By Type: Combination Therapy, Monotherapy
2) By Mechanism of Action: Bruton Tyrosine Kinase Inhibitors, Alkylating Agents, Deoxyribonucleic Acid Synthesis Inhibitors, Microtubule Inhibitors, Monoclonal Antibodies, Other Mechanisms
3) By Route of Administration: Oral, Parenteral
4) By Application: Hospital, Research Institute, Other Applications
Subsegments:
1) By Combination Therapy: Chemotherapy Combinations, Targeted Therapy Combinations, Immunotherapy Combinations
2) By Monotherapy: Single-Agent Chemotherapy, Targeted Therapy Monotherapy, Immunotherapy Monotherapy
What Trends Are Affecting The Expansion Of The Mantle Cell Lymphoma Therapeutics Market?
Leading companies operating within the mantle cell lymphoma therapeutics market are developing innovative products, such as kinase inhibitors, to address larger customer bases, increase sales, and boost revenue. A kinase inhibitor is a pharmaceutical agent designed to interfere with the activity of enzymes known as kinases. For instance, in January 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets). This medication is indicated for adult patients experiencing a recurrence or resistance to prior treatments for mantle cell lymphoma (MCL). Jaypirca distinguishes itself as a highly selective kinase inhibitor, employing a unique binding mechanism. Noted for its capability to reestablish BTK inhibition in patients with mantle cell lymphoma (MCL) who have undergone previous treatment with covalent BTK inhibitors like ibrutinib, acalabrutinib, or zanubrutinib, Jaypirca extends the advantages of targeting the BTK pathway.
Which Major Firms Influence Developments In The Mantle Cell Lymphoma Therapeutics Market?
Major companies operating in the mantle cell lymphoma therapeutics market are AstraZeneca plc, Celgene Corporation, Takeda Pharmaceutical Company Limited, Bayer Aktiengesellschaft, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Kite Pharma Inc., Gilead Sciences Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Merck & Co. Inc., Juno Therapeutics Inc., Nurix Therapeutics Inc., Janssen Biotech Inc., TG Therapeutics Inc., F. Hoffmann-La Roche AG, Astellas Pharma Inc., BeiGene Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Hutchison China MediTech Limited, Incyte Corporation
Read the full mantle cell lymphoma therapeutics market report here:
Which Region Is Forecast To Lead The Mantle Cell Lymphoma Therapeutics Market In Terms Of Market Size?
North America was the largest region in the global mantle cell lymphoma therapeutics market in 2025. The regions covered in the mantle cell lymphoma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Mantle Cell Lymphoma Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10813&type=smp
Browse Through More Reports Similar to the Global Mantle Cell Lymphoma Therapeutics Market 2026, By The Business Research Company
Mantle Cell Lymphoma Therapeutics Market Report 2026
Diffuse Large B Cell Lymphoma Therapeutics Market Report 2026
Emphysema Market Report 2026
https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model